Roche's Breast Cancer Drug Herceptin Faces Biosimilar Competition -Cinco Dias
05 December 2017 - 10:22PM
Dow Jones News
--Within a few weeks of each other, the U.S. Food and Drug
Administration and the European Medicines Agency have approved the
authorization of the sale of Herceptin biosimilars, Spain's Cinco
Dias reports.
--Herceptin is a drug developed by Roche Holding AG (ROG.EB) for
the treatment breast cancer.
--Cinco Dias says that on Dec. 1, the FDA approved the
biosimilar Ogivri, developed by Mylan NV (MYL). The news comes only
a few days after the European Medicines Agency authorized the
commercialization of Ontruzant on Nov. 20, developed by Samsung
Bioepis, a joint venture created by Samsung Electronics Co. Ltd.
(005930.SE) and Biogen Inc. (IIB).
--In general, the price for biosimilars is around 20% to 25%
lower than patented drugs, Cinco Dias reports, which could force
the Swiss company to lower its prices to fight competition in some
countries.
--Herceptin generated 5.9 billion euros ($6.99 billion) in sales
last year for Roche, it says.
Full story: http://bit.ly/2AS5WWj
Write to Barcelona editors at barcelonaeditors@dowjones.com
(END) Dow Jones Newswires
December 05, 2017 06:07 ET (11:07 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
Mylan NV (NASDAQ:MYL)
Historical Stock Chart
From Aug 2024 to Sep 2024
Mylan NV (NASDAQ:MYL)
Historical Stock Chart
From Sep 2023 to Sep 2024
Real-Time news about Mylan NV (NASDAQ): 0 recent articles
More Mylan N.V. (MM) News Articles